Monograph
C07AG01 - Labetalol |
Not porphyrinogenic |
NP |
Rationale
Alpha/beta-blocker. Several references stating non-porphyrinogenicity. Alpha/beta receptor blocker of choice in acute porphyria.
Chemical description
Alpha/beta - receptor blocking agent. Metabolized by CYP 2D6 dependent conjugation to glucuronide, excreted in urine and bile.Some oxidative metabolism may take place but a minor pathway. Less than 5% excreted in unchanged form in urine. Thunell, patient report (n=1): tolerated. Andersson, patient report (n=1): tolerated. South African list: use. French list: authorized. Kalman, Bonkowsky: believed to be safe. Michael Moore's list: safe. Moore MR, Hift RJ: Drugs in the acute porphyrias. Cell Mol Biol. 43:89, 1997: safe.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Luxembourg
Iceland
Finland
